These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 21864228)

  • 1. Bisphosphonate anticancer activity in multiple myeloma.
    Terpos E
    Anticancer Agents Med Chem; 2012 Feb; 12(2):123-8. PubMed ID: 21864228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonate therapy in the treatment of multiple myeloma.
    Lawson MA; Ashcroft J; Croucher PI
    Curr Pharm Des; 2010; 16(27):3028-36. PubMed ID: 20722619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential anticancer properties of bisphosphonates.
    Neville-Webbe HL; Gnant M; Coleman RE
    Semin Oncol; 2010 Jun; 37 Suppl 1():S53-65. PubMed ID: 20682373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonates in multiple myeloma: a network meta-analysis.
    Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
    Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can bisphosphonates improve outcomes in patients with newly diagnosed multiple myeloma?
    Morgan GJ
    Crit Rev Oncol Hematol; 2011 Feb; 77 Suppl 1():S24-30. PubMed ID: 21353177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential anticancer properties of bisphosphonates: insights from preclinical studies.
    Clezardin P
    Anticancer Agents Med Chem; 2012 Feb; 12(2):102-13. PubMed ID: 21864232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonate anticancer activity in prostate cancer and other genitourinary cancers.
    Saad F; Mulders P
    Anticancer Agents Med Chem; 2012 Feb; 12(2):129-36. PubMed ID: 21864229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease.
    Terpos E; Dimopoulos MA; Berenson J
    Crit Rev Oncol Hematol; 2011 Feb; 77 Suppl 1():S13-23. PubMed ID: 21353176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisphosphonates in multiple myeloma.
    Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
    Cochrane Database Syst Rev; 2010 Mar; (3):CD003188. PubMed ID: 20238320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bisphosphonates for Patients Diagnosed With Multiple Myeloma.
    Mhaskar R; Djulbegovic B
    JAMA; 2018 Oct; 320(14):1483-1484. PubMed ID: 30326511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The backbone of progress--preclinical studies and innovations with zoledronic acid.
    Green JR; Guenther A
    Crit Rev Oncol Hematol; 2011 Feb; 77 Suppl 1():S3-S12. PubMed ID: 21353178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonates for breast cancer.
    Pavlakis N; Stockler M
    Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisphosphonates in breast cancer: clinical activity and implications of preclinical data.
    Aft R
    Clin Adv Hematol Oncol; 2011 Mar; 9(3):194-205. PubMed ID: 21475125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticancer activity of bisphosphonates in breast cancer.
    Gnant M
    Anticancer Agents Med Chem; 2012 Feb; 12(2):114-22. PubMed ID: 21864231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical value of bisphosphonates in cancer therapy.
    Lüftner D; Henschke P; Possinger K
    Anticancer Res; 2007; 27(4A):1759-68. PubMed ID: 17649770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Bisphosphonates in the treatment of multiple myeloma].
    Stajszczyk M
    Przegl Lek; 2002; 59(1):37-42. PubMed ID: 12108045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bisphosphonates in lung cancer: can they provide benefits beyond prevention of skeletal morbidity?
    Hirsh V
    Anticancer Agents Med Chem; 2012 Feb; 12(2):137-43. PubMed ID: 21864233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-tumour activity of bisphosphonates in human myeloma cells.
    Shipman CM; Rogers MJ; Apperley JF; Graham R; Russell G; Croucher PI
    Leuk Lymphoma; 1998 Dec; 32(1-2):129-38. PubMed ID: 10037008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonates in oncology.
    Coleman RE; McCloskey EV
    Bone; 2011 Jul; 49(1):71-6. PubMed ID: 21320652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Bisphosphonates for myeloma patients].
    Miwa A
    Nihon Rinsho; 2007 Dec; 65(12):2315-37. PubMed ID: 18069279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.